Addiction, Alcohol, Author Interviews, Cannabis, Education, JAMA, Pediatrics, Social Issues, UCLA / 06.10.2022

MedicalResearch.com Interview with: [caption id="attachment_59623" align="alignleft" width="150"]Mitchell Wong, MD PhD Professor of Medicine Executive Vice Chair for Research Training, Department of Medicine Executive Co-Director, Specialty Training and Advanced Research (STAR) Program Director, UCLA CTSI KL2 Program UCLA Division of General Internal Medicine and Health Services Research Los Angeles, CA 90024 Dr. Wong[/caption] Mitchell Wong, MD PhD Professor of Medicine Executive Vice Chair for Research Training Department of Medicine Executive Co-Director, Specialty Training and Advanced Research (STAR) Program Director, UCLA CTSI KL2 Program UCLA Division of General Internal Medicine and Health Services Research Los Angeles, CA 90024 MedicalResearch.com: What is the background for this study? Response: It is estimated that social factors like poverty, education, and housing have a large impact on health. Yet, there are few interventions that exist to directly address those issues.  Schools are a promising solution since society already invests heavily in education and schools are an everyday part of most children’s lives.
Author Interviews, Clots - Coagulation, Heart Disease, Karolinski Institute, Kidney Disease / 06.10.2022

MedicalResearch.com Interview with: [caption id="attachment_59616" align="alignleft" width="150"]Juan Jesus Carrero Pharm PhD Professor of Epidemiology Cardio-renal Department of Medical Epidemiology and Biostatistics Karolinska Institutet, Stockholm Dr. Carrero[/caption] Juan Jesus Carrero Pharm PhD Professor of Epidemiology Cardio-renal Department of Medical Epidemiology and Biostatistics Karolinska Institutet, Stockholm MedicalResearch.com: What is the background for this study? What are the main findings?  Response: Concerns on the possibility of (direct oral anticoagulants)  DOAC-related nephropathy may limit its use. In this cohort study of non-valvular AF patients from routine clinical practice, initiation of DOAC vs (vitamin K antagonists) VKA was associated with more favorable kidney outcomes, i.e., a lower risk of the composite of kidney failure and sustained 30% eGFR decline, as well as a lower risk of AKI occurrence. In agreement with trial evidence, we also showed that DOAC vs VKA treatment was associated with a lower risk of major bleeding, but a similar risk of the composite of stroke, systemic embolism or death.
Author Interviews, Dermatology, Immunotherapy, NEJM, University of Pittsburgh / 06.10.2022

MedicalResearch.com Interview with: Rohit Aggarwal, MD, MS Rheumatology, Professor of Medicine Medical Director, Arthritis and Autoimmunity Center Sub-Specialty Education Coordinator Division of Rheumatology Department of Medicine University of Pittsburgh MedicalResearch.com: What is the background for this study? [caption id="attachment_59610" align="alignleft" width="150"]dermatomyositis-hand-2__dermnet-image One example of Dermatomyositis: DermNet image[/caption] Response: Dermatomyositis is a rare autoimmune inflammatory disease that affects muscles and skin, although muscular forms without skin symptoms and vice versa are also seen. The exact etiology of the disease is not known but is thought to be immune-mediated with many patients having highly specific autoantibodies. There is no cure for dermatomyositis, but several types of treatment have been successfully used in the last years including different kinds of immunosuppressants (e.g. steroids) and intravenous immune globulins (IVIG) to improve the patient’s condition. So far, none of these treatments was approved for use in dermatomyositis based on large, randomized, placebo-controlled trials. Their effectiveness was mainly deduced from clinical experience and from small clinical trials. The ProDERM study was the first large, pivotal, randomized placebo-controlled trial to evaluate the efficacy and safety of intravenous immune globulin (IVIG) in dermatomyositis patients.
Author Interviews, CDC, Cost of Health Care, Hepatitis - Liver Disease / 05.10.2022

MedicalResearch.com Interview with: William W. Thompson, Ph.D. Epidemiologist Division of Viral Hepatitis CDC MedicalResearch.com: What is the background for this study? Response: Prior to this analysis, we knew only an estimated 1.2 million persons initiated hepatitis C treatment with DAA agents in the United States during 2014–2020, far below the number needed to achieve national hepatitis C elimination goals. Further, the number of persons treated was highest in 2015 and declined to its lowest level in 2020. This analysis used a large national health care claims database to assess the level and timing of hepatitis C treatment among persons with diagnosed HCV infection with breakdowns by sex, age, race, insurance type (i.e., private, Medicaid, and Medicare), and by state.
Author Interviews, JAMA, NYU/NYMC, STD, USPSTF / 30.09.2022

MedicalResearch.com Interview with: [caption id="attachment_56129" align="alignleft" width="133"]Gbenga Ogedegbe, MD, MPH Dr. Adolph & Margaret Berger Professor of Population Health Director, Division of Health & Behavior Director Center for Healthful Behavior Change Department of Population Health NYU Langone Health NYU School of Medicine Dr. Ogedegbe[/caption] Gbenga Ogedegbe, MD, MPH Dr. Adolph & Margaret Berger Professor of Population Health Director, Division of Health & Behavior Director Center for Healthful Behavior Change Department of Population Health NYU Langone Health NYU School of Medicine Member of the U.S. Preventive Services Task Force   MedicalResearch.com: What is the background for this study? Response: Syphilis has become more common over the past 20 years, after reaching a record low in 2000. The Task Force found that screening people who are at increased risk for syphilis can identify the infection early so it can be treated before problems develop. For that reason, the Task Force recommends screening people who are at increased risk for syphilis infection.
Author Interviews, Brigham & Women's - Harvard, Melatonin, Pediatrics, Sleep Disorders / 28.09.2022

MedicalResearch.com Interview with: [caption id="attachment_59589" align="alignleft" width="150"]Rebecca Robbins, Ph.D. Instructor in Medicine Associate Scientist, Division of Sleep and Circadian Disorders Investigator, Division of Sleep and Circadian Disorders Departments of Medicine and Neurology Brigham and Women's Hospital Dr. Robbins[/caption] Rebecca Robbins, Ph.D. Instructor in Medicine Associate Scientist, Division of Sleep and Circadian Disorders Investigator, Division of Sleep and Circadian Disorders Departments of Medicine and Neurology Brigham and Women's Hospital MedicalResearch.com: What is the background for this study? Response: Teens face myriad challenges to sleep, ranging from biological factors, including a preference for later bedtimes and increased need for sleep, to social factors, including social pressures and increased academic workloads, all limiting teenagers in their ability to keep a healthy sleep schedule. In a nationally representative sample, we explored the prevalence of another potential barrier to sleep among teens, which are a set of beliefs that are held in the population, yet are actual counter to scientific principles regarding sleep and circadian rhythms.
Author Interviews, Cost of Health Care, COVID -19 Coronavirus, JAMA / 26.09.2022

MedicalResearch.com Interview with:

Allison Witman PhD Assistant Professor of Economics Economics & Finance Cameron School of Business University of North Carolina, Wilmington

Yu Wang PhD Assistant Professor Congdon School of Supply Chain, Business Analytics, & Information Systems Cameron School of Business University of North Carolina Wilmington David Cho PhD Assistant Professor of Management California State University, Fullerton

MedicalResearch.com: What is the background for this study? Response: The COVID-19 pandemic placed tremendous financial pressure on hospitals. Beginning in March of 2020, hospitals cancelled outpatient and elective procedures to accommodate surges in demand from COVID-19 patients. As these procedures account for more than 60% of an average hospital’s revenue, cancellation posed serious challenges to the financial health of hospitals. Revenue from COVID-19 patients may have partially offset these effects, but the American Hospital Association estimated a total loss of $202.6 billion by American hospitals between March and June 2020. In response, the U.S. government created large federal assistance programs aimed to stabilize hospitals’ financial situation as their ability to maintain operations was critical to the health of the nation. Due to differences in hospital characteristics, certain hospitals such as rural hospitals and those serving a higher share of Medicaid and uninsured patients (e.g., safety net hospitals) may have been more financially susceptible to the effects of the pandemic. These hospitals that serve vulnerable patient populations historically have had lower profit margins and were candidates for targeted COVID relief funding (e.g., Safety Net Hospitals Payments, a $10 billion component of the Provider Relief Fund).
Author Interviews, Diabetes, Sleep Disorders, Weight Research / 26.09.2022

MedicalResearch.com Interview with: [caption id="attachment_59573" align="alignleft" width="160"]Steven K. Malin, PhD, FACSM (he/him) Associate Professor  Department of Kinesiology and Health | School of Arts and Sciences  Division of Endocrinology, Metabolism and Nutrition | Robert Wood Johnson Medical School Institute of Translational Medicine and Science  New Brunswick, NJ 08901 Dr. Malin[/caption] Steven K. Malin, PhD, FACSM (he/him) Associate Professor Department of Kinesiology and Health | School of Arts and Sciences Division of Endocrinology, Metabolism and Nutrition | Robert Wood Johnson Medical School Institute of Translational Medicine and Science New Brunswick, NJ 08901 MedicalResearch.com: What is the background for this study? Response: Type 2 diabetes is a condition where blood glucose (sugar) is elevated in the  blood. This can be problematic as it leads to blood vessel damage and the promotion of cardiovascular disease. Nearly 30 million people  in the U.S. have type 2 diabetes, making it a major public health issue. The cause is not entirely clear, but many, including our team view insulin resistance as a central culprit. Insulin resistance is when the body does not respond well to the hormone insulin. Insulin is vital because it promotes glucose uptake into tissues, like skeletal muscle. Two reasons that are often used to explain the development of insulin resistance include: poor diet (e.g. high sugar and/or high fat coupled with excess calories) and a lack of physical activity. However, more recently, a lack of sleep has been raised as another critical behavioral factor contributing to insulin resistance. Thus, targeting a healthy diet, activity and sleep pattern is thought to prevent the transition from health to insulin resistance and type 2 diabetes.
Author Interviews / 23.09.2022

It isn’t always easy to decide what kind of career you should pursue, particularly when there are so many options available. A lot of people can find it overwhelming to think about what they want to do with their life, and finding a role that makes them happy while providing enough security that they are comfortable isn’t always straightforward. Although there are several industries and specialist fields you can explore, one area to work in that can offer a lot is the healthcare sector. Working in healthcare is not only a career choice that can provide numerous interesting job opportunities, but it is also one that you can be proud of. This industry is vital to keeping members of society healthy and plays an active part in saving people’s lives, too. With the innovations and discoveries in medical science, it’s also a fascinating area to work in, with plenty of impressive trailblazers that you can call your colleagues. If this all sounds good to you so far, you might want to consider these further reasons to at least consider a career in the healthcare sector.
Aging, Author Interviews, Brigham & Women's - Harvard, Frailty, Geriatrics, JAMA / 22.09.2022

MedicalResearch.com Interview with: [caption id="attachment_59544" align="alignleft" width="150"]Ariela Orkaby, MD, MPH Geriatrics & Preventive Cardiology Associate Epidemiologist Division of Aging, Brigham and Women's Hospital  Assistant Professor of Medicine, Harvard Medical School Dr. Orkaby[/caption] Ariela Orkaby, MD, MPH Geriatrics & Preventive Cardiology Associate Epidemiologist Division of Aging, Brigham and Women's Hospital Assistant Professor of Medicine, Harvard Medical School MedicalResearch.com: What is the background for this study? Response: As the population is living longer, there is increased risk of frailty and vulnerability. Frailty is defined as reduced physiological reserve and decreased ability to cope with even an acute stress. Up to half of adults over the age of 85 are living with frailty and preventative measures are greatly needed. We tested the effect of vitamin D and marine omega-3 fatty acid supplementation on the risk of developing frailty in healthy older adults in the US enrolled in the VITamin D and OmegA-3 TriaL (VITAL) trial.
Alzheimer's - Dementia, Author Interviews, Infections, Parkinson's / 22.09.2022

MedicalResearch.com Interview with: [caption id="attachment_59522" align="alignleft" width="150"]Jiangwei Sun Ph Postdoctoral researcher in Prof. Jonas Ludvigsson's group Department of Medical Epidemiology and Biostatistics Karolinska Institutet Dr. Sun[/caption] Jiangwei Sun PhD Postdoctoral researcher in Prof. Jonas Ludvigsson's group Department of Medical Epidemiology and Biostatistics Karolinska Institutet MedicalResearch.com: What is the background for this study? Response: A potential infectious etiology has been hypothesized for neurodegenerative diseases, as findings in animal studies have demonstrated that infectious processes might impact pathogenesis, phenotype, and progression of neurodegenerative disease. The extrapolation of such findings to a human context is however not straightforward. previous studies have mostly examined the role of specific pathogens on a specific neurodegenerative disease, e.g., herpesvirus for Alzheimer’s disease, and influenza, hepatitis C virus, and Helicobacter pylori for PD, with inconclusive results. Although several studies have also assessed associations between infectious diseases and risk of dementia and AD, influence of potential surveillance bias (greater-than-expected surveillance of disease after infections) and reverse causation (due to for example diagnostic delay of neurodegenerative diseases) on the associations was not always fully addressed. Therefore, whether infection is indeed a risk factor rather a comorbidity or secondary event of neurodegenerative disease remains unknown. In contrast to Alzheimer’s disease, and Parkinson’s disease, the potential link between infection and ALS has been less explored.
Author Interviews, Cancer Research, Dermatology, Melanoma / 22.09.2022

MedicalResearch.com Interview with: “Prof. Ronit Satchi-Fainaro, the Director of the Cancer Biology Research Center led this study with an outstanding PhD student, Sabina Pozzi” Prof. Ronit Satchi-Fainaro, Ph.D. Head, Cancer Research and Nanomedicine Laboratory Kurt and Herman Lion Chair in Nanosciences and Nanotechnologies Director, Cancer Biology Research Center Department of Physiology and Pharmacology Sackler Faculty of Medicine Sagol School of Neuroscience Tel Aviv University, Tel Aviv 69978, Israel MedicalResearch.com: What is the background for this study? Response: Cutaneous melanoma is the deadliest of all skin cancers, especially due to its tendency to invade and develop metastases with an incidence of brain metastasis development of 40% to 50% in patients with melanoma stage IV (although the incidence post mortem is 70–90%). We know that the brain microenvironment represents the first line of reaction in favor or against the tumor due to its dual ability to generate an immune-stimulatory or immunosuppressive niche, which will ultimately determine the establishment and growth of melanoma brain metastasis. Among the brain-resident cells, astrocytes are responsible for the maintenance of the brain homeostasis, and subsequent to melanoma brain colonization, they sustain and foster the growth of melanoma cells
Author Interviews, Diabetes, JAMA, Pediatrics / 20.09.2022

MedicalResearch.com Interview with: [caption id="attachment_59555" align="alignleft" width="150"]Michael Cabana, M.D., M.A., M.P.H Professor of Pediatrics Albert Einstein College of Medicine Physician-in-chief at the Children's Hospital at Montefiore Chair of the Department of Pediatrics at the Albert Einstein College of Medicine. Dr. Cabana joined the U.S. Preventive Services Task Force in January 2019 Dr. Cabana[/caption] Michael Cabana, M.D., M.A., M.P.H Professor of Pediatrics Albert Einstein College of Medicine Physician-in-chief at the Children's Hospital at Montefiore Chair of the Department of Pediatrics at the Albert Einstein College of Medicine. Dr. Cabana joined the U.S. Preventive Services Task Force in January 2019 MedicalResearch.com: What is the background for this study? Response: Prediabetes and type 2 diabetes have historically been far more common in adults, but the number of children and teens who have these conditions is rising. However, there is still very limited research on whether screening, early detection, and early treatment of diabetes will improve a child’s long-term health. Due to this lack of evidence, the Task Force was unable to assess the benefits and harms of screening, particularly in Black, Hispanic, American Indian, and Pacific Islander populations, who are at a significantly higher risk of developing type 2 diabetes. We are calling for more research on this important topic.
Author Interviews, Biogen, NEJM, Rheumatology / 15.09.2022

MedicalResearch.com Interview with: [caption id="attachment_59551" align="alignleft" width="150"]Nathalie Franchimont, M.D., Ph.D. Senior Vice President, Head of Multiple Sclerosis and Immunology Head of the Multiple Sclerosis and Immunology Development Unit Biogen Dr. Franchimont[/caption] Nathalie Franchimont, M.D., Ph.D. Senior Vice President, Head of Multiple Sclerosis and Immunology Head of the Multiple Sclerosis and Immunology Development Unit Biogen MedicalResearch.com: What is the background for this study? What are the main findings? Response: Systemic lupus erythematosus (SLE) is a chronic autoimmune disease that affects multiple organ systems. Rash and arthritis are among the most frequent manifestations of the disease and severe organ damage can also occur especially when organs like the kidney are affected. Litifilimab (known as BIIB059) is a monoclonal antibody being studied for the potential treatment of SLE and cutaneous lupus erythematosus (CLE). The Phase 2 LILAC study evaluated litifilimab versus placebo in two parts: Part A in participants who have SLE with active joint and skin manifestations; and Part B in participants with active CLE, including chronic and subacute subtypes, with or without other organ involvement. Results from the SLE portion of the study (Part A) show litifilimab met the study’s primary endpoint by significantly reducing total active joint count compared to placebo. Total active joint count was defined as the total number of tender or swollen joints. Litifilimab was generally well tolerated, with most reported adverse events (AEs) rated as mild or moderate. Note, this Phase 2 trial was not powered to assess secondary endpoints. Based on these positive Phase 2 results, Biogen is currently enrolling participants into the Phase 3 TOPAZ-1 and TOPAZ-2 studies, which will evaluate the efficacy and safety of litifilimab in participants with active SLE worldwide. Part B results from LILAC were published separately in NEJM on July 28, 2022 and expand the body of evidence supporting litifilimab as a potential first-in-class therapy for cutaneous lupus erythematosus in addition to SLE.
Aging, Author Interviews, Brigham & Women's - Harvard, Frailty, Geriatrics, JAMA, Medical Research Centers, Supplements / 15.09.2022

MedicalResearch.com Interview with: [caption id="attachment_59545" align="alignleft" width="150"]Ariela Orkaby, MD, MPH Geriatrics & Preventive Cardiology Associate Epidemiologist Division of Aging, Brigham and Women's Hospital  Assistant Professor of Medicine, Harvard Medical School Dr. Orkaby[/caption] Ariela Orkaby, MD, MPH Geriatrics & Preventive Cardiology Associate Epidemiologist Division of Aging, Brigham and Women's Hospital Assistant Professor of Medicine, Harvard Medical School MedicalResearch.com: What is the background for this study? Response: As the population is living longer, there is increased risk of frailty and vulnerability. Frailty is defined as reduced physiological reserve and decreased ability to cope with even an acute stress. Up to half of adults over the age of 85 are living with frailty and preventative measures are greatly needed. We tested the effect of vitamin D and marine omega-3 fatty acid supplementation on the risk of developing frailty in healthy older adults in the US enrolled in the VITamin D and OmegA-3 TriaL (VITAL) trial.
Author Interviews, Geriatrics, JAMA / 15.09.2022

MedicalResearch.com Interview with: [caption id="attachment_59532" align="alignleft" width="150"]Jing Li, PhD Assistant Professor of Health Economics The Comparative Health Outcomes, Policy and Economics (CHOICE) Institute University of Washington School of Pharmacy Dr. Jing Li[/caption] Jing Li, PhD Assistant Professor of Health Economics The Comparative Health Outcomes, Policy and Economics (CHOICE) Institute University of Washington School of Pharmacy MedicalResearch.com: What is the background for this study? Response: Dementia and other cognitive impairment are highly prevalent among older adults in the U.S. and globally, and have been linked to deficiencies in decision-making, especially financial decision-making. However, little is known about the extent to which older adults with cognitive impairment manage their own finances and the characteristics of the assets they manage.
Author Interviews, Pulmonary Disease, Surgical Research / 13.09.2022

MedicalResearch.com Interview with: Ms. Sara Buttery Research Physiotherapist at Royal Brompton & Harefield NHS Foundation Trust University of the West of England London, England, UK MedicalResearch.com: What is the background for this study? Would you describe the BVLR technique? Response: The CELEB trial is a multicentre randomised controlled trial that was carried out at five centres across the UK, with the objective of investigating if Lung volume reduction surgery (LVRS) is significantly superior to Bronchoscopic lung volume reduction (BLVR) in people who are suitable for both procedures. BLVR is a minimally invasive method of lung volume reduction whereby a fibreoptic camera is passed through the mouth, rather than by an incision in the chest wall as is the case with LVRS. The CELEB trial compared endobronchial valves (EBVs) as a type of BLVR, to LVRS. EBVs are designed to prevent airflow into the treated lobe, but allow air and mucus to exit. EBV treatment can be carried out under general anaesthetic or sedation. The primary outcome for the CELEB trial was the iBODE index score at 12 months post procedure, as a measure of disease severity.
Author Interviews, Cost of Health Care, Dermatology, JAMA / 08.09.2022

MedicalResearch.com Interview with: [caption id="attachment_59485" align="alignleft" width="150"]Jane M. Zhu, M.D., M.P.P., M.S.H.P. Assistant Professor of Medicine Division of General Internal Medicine and Geriatrics School of Medicine Oregon Health & Science University Portland, Oregon Dr. Zhu[/caption] Jane M. Zhu, M.D., M.P.P., M.S.H.P. Assistant Professor of Medicine Division of General Internal Medicine and Geriatrics School of Medicine Oregon Health & Science University Portland, Oregon MedicalResearch.com: What is the background for this study? Response: Private equity (PE) acquisitions of physician practices are accelerating across many specialties, but there is still little robust evidence on the effects of these acquisitions. Concerns about PE involvement is predicated on the fact that these firms expect high annual returns, which require either reducing costs or increasing revenue, or both. Using PE acquisition data from 2016-2020, linked to commercial claims data, we sought to understand what common mechanisms of revenue generation were being adopted after private equity acquisition of physician practices.
Author Interviews, Exercise - Fitness, Genetic Research, Lifestyle & Health, Nature / 08.09.2022

MedicalResearch.com Interview with: [caption id="attachment_59514" align="alignleft" width="100"]Marcel den Hoed, PhD Researcher,Department of Immunology, Genetics and Pathology Uppsala University Dr. den Hoed[/caption] Marcel den Hoed, PhD Researcher,Department of Immunology, Genetics and Pathology Uppsala University MedicalResearch.com: What is the background for this study? What are the main findings? Response: In this paper we performed a multi-ancestry meta-analysis of 51 genome-wide association studies, in data from over 700,000 individuals. This yielded 11 DNA regions that are robustly associated with self-reported moderate-to-vigorous intensity physical activity during leisure time (MVPA), and 88 DNA regions for self-reported leisure screen time (LST). Around half of the identified DNA regions are also associated with objectively assessed physical activity traits in data from the UK Biobank. Causal inference using a Mendelian randomization approach subsequently showed bidirectional causal effects between LST and body mass index (BMI), with the effect of LST on BMI being 2-3-fold larger than vice versa. Less LST and more MVPA protect from diabetes, attention deficit hyperactivity disorder, depression, and earlier age at death, with all causal effects of MVPA and leisure screen time being mediated or confounded by BMI. Further analyses showed that DNA regions associated with LST are more often located close to genes whose expression in skeletal muscle is altered by strength training than expected by chance, suggesting that these genes may influence the likelihood of adopting an active lifestyle by influencing the response to training.
Author Interviews, Brigham & Women's - Harvard, Cancer Research, JAMA, Lancet, Lung Cancer, Medical Imaging, Technology / 07.09.2022

MedicalResearch.com Interview with: [caption id="attachment_59510" align="alignleft" width="200"]Raymond H. Mak, MD Radiation Oncology Disease Center Leader for Thoracic Oncology Director of Patient Safety and QualityDirector of Clinical Innovation Associate Professor, Harvard Medical School Cancer - Radiation Oncology, Radiation Oncology Department of Radiation Oncology Brigham and Women's Hospital Dr. Mak[/caption] Raymond H. Mak, MD Radiation Oncology Disease Center Leader for Thoracic Oncology Director of Patient Safety and QualityDirector of Clinical Innovation Associate Professor, Harvard Medical School Cancer - Radiation Oncology, Radiation Oncology Department of Radiation Oncology Brigham and Women's Hospital MedicalResearch.com: What is the background for this study? What is the algorithm detecting? Response: Lung cancer, the most common cancer worldwide is highly lethal, but can be treated and cured in some cases with radiation therapy.  Nearly half of lung cancer patients will eventually require some form of radiation therapy, but the planning for a course of radiation therapy currently entails manual, time-consuming, and resource-intensive work by highly trained physicians to segment (target) the cancerous tumors in the lungs and adjacent lymph nodes on three-dimensional images (CT scans). Prior studies have shown substantial variation in how expert clinicians delineate these targets, which can negatively impact outcomes and there is a projected shortage of skilled medical staff to perform these tasks worldwide as cancer rates increase. To address this critical gap, our team developed deep learning algorithms that can automatically target lung cancer in the lungs and adjacent lymph nodes from CT scans that are used for radiation therapy planning, and can be deployed in seconds. We trained these artificial intelligence (AI) algorithms using expert-segmented targets from over 700 cases and validated the performance in over 1300 patients in external datasets (including publicly available data from a national trial), benchmarked its performance against expert clinicians, and then further validated the clinical usefulness of the algorithm in human-AI collaboration experiments that measured accuracy, task speed, and end-user satisfaction.
Author Interviews, Cancer Research, JAMA / 06.09.2022

MedicalResearch.com Interview with: [caption id="attachment_59506" align="alignleft" width="130"]Samir Parekh, MBBS Hematology-Oncology, Cancer Director of Translational Research in Myeloma and Co-leader of the Cancer Clinical Investigation program The Tisch Cancer Institute Icahn School of Medicine at Mount Sinai Dr. Parekh[/caption] Samir Parekh, MBBS Hematology-Oncology, Cancer Director of Translational Research in Myeloma and Co-leader of the Cancer Clinical Investigation program The Tisch Cancer Institute Icahn School of Medicine at Mount Sinai MedicalResearch.com: What is the background for this study? What are the main findings? Response: Clinical outcomes for myeloma patients patients have improved significantly over the past decade with the introduction and success of newer immunomodulatory treatments such as CART cell therapy and bispecific antibodies. Strategies are needed to determine the best treatment options for patients relapsing or unresponsive to initial courses of these types of therapies. We analyzed the outcomes of patients relapsing after bispecific antibody therapy for myeloma. Our data shows that sequencing of bispecific antibodies or CART after initial bispecific failure can effectively salvage patients and lead to excellent outcomes in myeloma. This provides the foundation for future studies combining this new class of immunotherapy with CART or additional bispecific antibodies to improve outcomes in myeloma.
Author Interviews, Heart Disease, JAMA, Primary Care, Stroke, USPSTF / 06.09.2022

MedicalResearch.com Interview with: [caption id="attachment_59503" align="alignleft" width="150"]Katrina E. Donahue, M.D., M.P.H. Professor and Vice Chair of Research Chapel Hill Department of Family Medicine University of North Carolina Dr. Donahue joined the U.S. Preventive Services Task Force in January 2020. Dr. Donahue[/caption] Katrina E. Donahue, M.D., M.P.H. Professor and Vice Chair of Research Chapel Hill Department of Family Medicine University of North Carolina Dr. Donahue joined the U.S. Preventive Services Task Force in January 2020. MedicalResearch.com: What is the background for this study? What are the main findings? Response: Heart disease and stroke are the leading causes of death in the U.S. The Task Force found that people who are 40 to 75 years old and at high risk for heart disease should take a statin to help protect their health. People in this age group who are at increased risk but not high risk should make an individual decision with their healthcare professional about whether taking a statin is right for them. There is not enough research to determine whether statins are beneficial for people 76 years and older.
Author Interviews, Nature, Stem Cells / 05.09.2022

MedicalResearch.com Interview with: [caption id="attachment_59492" align="alignleft" width="150"]Gianluca Amadei PhD Post-Doctoral Fellow University of Cambridge, UK Dr. Amadei[/caption] Gianluca Amadei PhD Post-Doctoral Fellow University of Cambridge, UK MedicalResearch.com: What is the background for this study? What are the main findings? Response: The background of this study is that we tried to build a structure that looks and develops like a real mouse embryo using different kinds of mouse stem cells. The main findings are that the resulting structures develop the entire embryonic body axis and the extraembryonic tissues that are required to support embryonic development. Our structures develop to a stage comparable to 8.5 days of embryonic development of the natural mouse embryos and have a brain and neural tube, a beating heart-like structure, gut and primordial germ cells.
Author Interviews, NEJM, Pulmonary Disease, Tobacco Research, University of Michigan / 04.09.2022

MedicalResearch.com Interview with: [caption id="attachment_59488" align="alignleft" width="125"]Meilan K Han MD, MS Henry Sewall Professor of Medicine Professor of Internal Medicine and Section Head Division of Pulmonary and Critical Care Medicine, Medical School University of Michigan Dr. Han[/caption] Meilan K Han MD, MS Henry Sewall Professor of Medicine Professor of Internal Medicine and Section Head Division of Pulmonary and Critical Care Medicine, Medical School University of Michigan MedicalResearch.com: What is the background for this study? What are the main findings? Response: In the NIH sponsored SPIROMICS study we demonstrated that symptomatic, tobacco exposed individuals have frequent exacerbations. Many of these individuals are treated with the same inhaled medications that have shown benefit in COPD, but we don’t have any evidence basis for this practice.
Addiction, Author Interviews, Methamphetamine / 02.09.2022

Methamphetamine is a highly addictive stimulant drug that is often used recreationally. It is a central nervous system (CNS) stimulant used to treat ADHD and narcolepsy. The drug is highly addictive and should be used only under the supervision of a healthcare provider. Meth mouth is a slang term used to describe the dental problems resulting from methamphetamine abuse. The long-term use of methamphetamine can lead to meth mouth due to the detrimental effects the drug has on oral health. What Are the Signs of Meth Mouth? The signs of meth mouth can vary depending on the severity of the condition. However, some common signs and symptoms of meth mouth include:
  • Severe tooth decay
  • Tooth loss
  • Missing teeth
  • Broken teeth
  • Cracked teeth
  • Yellow or brown stains on teeth
  • Gum disease
  • Dry mouth
  • Bad breath
  • Meth sores
Aging, Annals Internal Medicine, Author Interviews, NIH, Nutrition / 01.09.2022

MedicalResearch.com Interview with: [caption id="attachment_59475" align="alignleft" width="150"]Maki Inoue-Choi, Ph.D., M.S., R.D. Staff Scientist Metabolic Epidemiology Branch National Institutes of Health Dr. Maki Inoue-Choi,[/caption] Maki Inoue-Choi, Ph.D., M.S., R.D. Staff Scientist Metabolic Epidemiology Branch National Institutes of Health MedicalResearch.com: What is the background for this study? Response: Tea is rich in bioactive compounds that can possibly protect against health conditions such as cancer and heart disease. A lower risk of death was seen among tea drinkers than non-drinkers in previous studies, but these were largely in populations where green tea drinking is common. In contrast, the studies in populations where black tea drinking is more common have been limited and the findings from these studies have been inconsistent.
Author Interviews, Cost of Health Care, JAMA, Pharmaceutical Companies / 31.08.2022

MedicalResearch.com Interview with: [caption id="attachment_59466" align="alignleft" width="200"]Prof. Katharina Blankart, PhD Faculty of Economics and Business Administration University of Duisburg-Essen Essen, Germany Prof. Blankart[/caption] Prof. Katharina Blankart, PhD Faculty of Economics and Business Administration University of Duisburg-Essen Essen, Germany MedicalResearch.com: What is the background for this study? Response: Given the high drug prices and policy discussions, we were interested whether the US may miss opportunities from medical innovation in availability of medicines compared to Germany. Since 2011, Germany has a unique way to determine value of new medicines after regulatory approval and to negotiate prices. We aimed to find out differences in availability of medicines in these two countries and timing of availability. We evaluated the differences in timing of availability and to characterize medicines not available to one of the two countries.
Author Interviews, Heart Disease, NEJM / 30.08.2022

MedicalResearch.com Interview with: [caption id="attachment_59461" align="alignleft" width="128"]Dr Holly Morgan M.B., B.Ch. Clinical Research Fellow and REVIVED investigator King's College London Dr. Morgan[/caption] Dr Holly Morgan M.B., B.Ch. Clinical Research Fellow and REVIVED investigator King's College London MedicalResearch.com: What is the background for this study? Response: Coronary artery disease is the commonest cause of heart failure.  Whilst individually tailored pharmacological and device therapy (optimal medical therapy, OMT) is the cornerstone of management of ischemic heart failure, rates of death and hospitalization for heart failure remain unacceptably high in this population.  Given the causative relationship between coronary disease and heart failure, coronary revascularization has long been considered as a treatment option for these patients.  Whilst there is randomized evidence to support surgical revascularization with coronary artery bypass grafting (1), none previously existed for percutaneous coronary intervention (PCI) in stable ischemic left ventricular dysfunction. Despite this, patients are frequently offered PCI in this setting (particularly if unsuitable for surgery); driven by the belief that hibernating myocardium will improve in function if blood flow is restored, regardless of the revascularization method.  This approach was supported in some international guidelines, though recommendations varied. The REVIVED-BCIS2 trial aimed to establish whether revascularization with PCI in addition to OMT would improve event free survival in patients with ischemic left ventricular dysfunction, when compared to OMT alone (2).  Inclusion criteria included a left ventricular ejection fraction of ≤35%, extensive coronary artery disease (British Cardiovascular Intervention Society jeopardy score ≥6, indicating significant stenoses in the left main coronary artery, proximal left anterior descending coronary artery, dominant circumflex artery, disease in multiple vessels or a combination of these) and viability in at least four dysfunctional myocardial segments which were amenable to PCI.  The main exclusion criteria were acute myocardial infarction within 4 weeks of randomisation, angina which limited the patient’s quality of life or decompensated heart failure or sustained ventricular arrhythmia within 72 hours. The primary composite outcome was all-cause death or hospitalization for heart failure; minimum follow up was 24 months.  Key secondary outcomes included the change in left ventricular ejection fraction from baseline to follow-up at six and twelve months, myocardial infarction, unplanned revascularization and quality of life assessed with the Kansas City Cardiomyopathy Questionnaire and EQ-5D-5L.